Rocket Pharmaceuticals Inc RCKT announced an update Tuesday related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the clinical triad of cardiomyopathy (stiff heart muscles), skeletal myopathy (weakness) and intellectual disability.
A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE). The patient passed away after an acute systemic infection.
Rocket Pharmaceuticals shares fell 62.8% to close at $2.33 on Tuesday.
These analysts made changes to their price targets on Rocket Pharmaceuticals following the news.
- Jefferies analyst Andrew Tsai downgraded Rocket Pharmaceuticals from Buy to Hold and lowered the price target from $29 to $2.5.
- Chardan Capital analyst Geulah Livshits maintained the stock with a Buy and cut the price target from $46 to $17.
Considering buying RCKT stock? Here’s what analysts think:
Read This Next:
Photo via Shutterstock
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.